Cogent Biosciences(US:COGT)2025-11-03 14:13Financial Position - As of September 30, 2025, cash, cash equivalents, and marketable securities were $390.9 million, up from $345.5 million as of June 30, 2025, indicating a strong cash position to fund operations into 2027[10]. - Total assets as of September 30, 2025, were $425.9 million, compared to $327.9 million as of December 31, 2024[21]. - Total stockholders' equity increased to $302.5 million as of September 30, 2025, from $256.3 million at the end of 2024[21]. Expenses - Research and development expenses for Q3 2025 were $69.0 million, compared to $63.6 million in Q3 2024, reflecting increased costs for ongoing clinical trials[11]. - General and administrative expenses rose to $14.4 million in Q3 2025 from $11.8 million in Q3 2024, primarily due to organizational growth[12]. Losses - The net loss for Q3 2025 was $80.9 million, compared to a net loss of $70.6 million for the same period in 2024[13]. Fundraising - The company successfully closed a public offering of 25,555,556 shares at $9.00 per share, generating net proceeds of $215.8 million[8]. Clinical Trials - Anticipated top-line results from the Phase 3 PEAK trial are expected in November 2025, with APEX trial results expected in December 2025[9][14]. - The company received Breakthrough Therapy Designation for bezuclastinib in NonAdvSM patients, with an NDA filing planned for year-end 2025[4]. - The company plans to initiate a Phase 1 trial for its novel ErbB2 inhibitor in November 2025 following FDA clearance[7].